Lixte Biotechnology Ownership
| LIXT Stock | USD 2.48 0.02 0.81% |
Shares in Circulation | First Issued 2006-03-31 | Previous Quarter 2.2 M | Current Value 2.2 M | Avarage Shares Outstanding 530.9 M | Quarterly Volatility 1.4 B |
Lixte |
Lixte Stock Ownership Analysis
About 20.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 1.73. Lixte Biotechnology last dividend was issued on the 20th of November 2020. The entity had 1:10 split on the 5th of June 2023. Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company was founded in 2005 and is based in Pasadena, California. Lixte Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people. To find out more about Lixte Biotechnology Holdings contact Bastiaan MSc at 631 830 7092 or learn more at https://lixte.com.Besides selling stocks to institutional investors, Lixte Biotechnology also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Lixte Biotechnology's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Lixte Biotechnology's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Lixte Biotechnology Quarterly Liabilities And Stockholders Equity |
|
Lixte Biotechnology Insider Trades History
About 20.0% of Lixte Biotechnology Holdings are currently held by insiders. Unlike Lixte Biotechnology's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Lixte Biotechnology's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Lixte Biotechnology's insider trades
Lixte Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Lixte Biotechnology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Lixte Biotechnology Holdings backward and forwards among themselves. Lixte Biotechnology's institutional investor refers to the entity that pools money to purchase Lixte Biotechnology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Hightower Advisors, Llc | 2024-09-30 | 99.4 K | Fny Investment Advisers, Llc | 2024-06-30 | 50.3 K | Ethos Financial Group Llc | 2024-09-30 | 24.8 K | Geode Capital Management, Llc | 2024-09-30 | 17.2 K | Tower Research Capital Llc | 2024-09-30 | 2.1 K | Ubs Group Ag | 2024-09-30 | 367 | Bank Of America Corp | 2024-09-30 | 16.0 | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 0.0 | Wells Fargo & Co | 2024-06-30 | 0.0 |
Lixte Biotechnology Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lixte Biotechnology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lixte Biotechnology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Lixte Biotechnology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Lixte Biotechnology Outstanding Bonds
Lixte Biotechnology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Lixte Biotechnology uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Lixte bonds can be classified according to their maturity, which is the date when Lixte Biotechnology Holdings has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Lixte Biotechnology Corporate Filings
F4 | 22nd of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 10th of January 2025 Other Reports | ViewVerify | |
8K | 6th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 12th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Lixte Stock Analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.